Optomed Oyj

Optomed Plc's Nomination Board has proposed several items for the next Annual General Meeting. They suggest that the Board of Directors should have seven members for the term ending at the 2026 meeting. Anna Tenstam has indicated she will not seek re-election. The proposed remuneration for the Board remains unchanged, with 40% paid in Optomed shares and 60% in cash, and a meeting fee of EUR 300 for committee chairmen and EUR 200 for committee members per meeting. The remuneration will be paid annually in August after the H1 report is released. The Nomination Board includes Petri Salonen as an expert member and Vesa Vanha-Honko as chairman. Optomed is a Finnish company specializing in handheld fundus cameras and related software, focusing on eye-screening devices and solutions for blinding eye diseases.

Optomed Plc has announced a change in its shareholdings as reported by Danske Bank A/S, which now holds 4.86% of Optomed's shares and voting rights as of November 12, 2024. Previously, Danske Bank held 5.08%. The total number of Optomed's registered shares is 19,630,397, with each share granting one vote. The notification includes details of the shares and voting rights distribution, with the majority held by Finnish Fund and a minor portion by Danica Pension Livsforsikringsaktie. Optomed is a Finnish company specializing in handheld fundus cameras and related software, focusing on eye disease diagnostics and operating in over 60 countries. Further inquiries can be directed to Sakari Knuutti, CFO of Optomed.

Optomed Plc announced that a total of 62,900 new shares have been subscribed through its 2018C stock options as of October 25, 2024, amounting to a subscription price of EUR 220,150. These shares have been added to the reserve for invested unrestricted equity. Following the registration, the total number of shares is now 19,693,297. The new shares were registered in the Trade Register on November 13, 2024, and will be traded on Nasdaq Helsinki alongside existing shares starting November 14, 2024. Optomed is a Finnish medical technology company specializing in handheld fundus cameras and software, focusing on eye disease diagnostics and operating in over 60 countries. For more information, contact Sakari Knuutti, CFO, at sakari.knuutti@optomed.com.

Optomed Plc announced that it has received a EUR 1.5 million order from a US screening service provider, prompting the company to revise its full-year 2024 revenue outlook. Initially expecting a revenue decrease from 2023, Optomed now anticipates revenue to remain at the same level as the previous year. The order is a traditional device capex transaction without AI services or recurring revenue. Due to low device stock levels, Optomed may face limitations in making additional large capex deliveries in the fourth quarter of 2024. Optomed is a Finnish medical technology company specializing in handheld fundus cameras and screening software, with operations in Finland, the US, and China, and sales in over 60 countries.

Optomed Plc reported a decline in financial performance for Q3 2024, with revenue decreasing by 26.3% compared to Q3 2023. The Devices segment saw a significant drop of 55.5% in revenue, mainly due to the absence of large orders that had been present in the previous year. The Software segment experienced a smaller decline of 4.0%. The company's gross margin fell to 54.4% from 67.4%, influenced by an inventory revaluation. EBITDA was reported at EUR -814 thousand, a sharp decline from the previous year. Optomed's net debt increased by 70.6%, reaching EUR -8,343 thousand. Despite these challenges, the company highlighted progress in the oculomics field and the commercialization of Aurora AEYE, with new market opportunities and strategic partnerships. Optomed expects a decrease in full-year 2024 revenue compared to 2023. The company maintains a strong cash position of EUR 11 million. The Annual General Meeting elected the Board of Directors and confirmed no dividend payout for 2023. Optomed continues to focus on innovation in healthcare diagnostics and strategic partnerships.